Patents by Inventor Paul Ditullio
Paul Ditullio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10974692Abstract: A seatbelt system comprising a buckle; a spool with a ratchet wheel and webbing that is windable onto or off of the spool as the spool rotates. A control mechanism is operatively engaged with a pawl located proximate the ratchet wheel. When the control mechanism is in a first condition, the pawl is disengaged from the ratchet wheel and the ratchet wheel and spool are rotatable to wind the webbing onto or off of the spool. When the control mechanism is in a second condition, the pawl is moved into engagement with the ratchet wheel and the ratchet wheel and spool are only able to rotate the webbing onto the spool. The control mechanism includes electronic switches and sensors that have to be actuated along with engaging the locking tongue in the buckle in order to move the pawl into engagement with the ratchet wheel.Type: GrantFiled: October 3, 2018Date of Patent: April 13, 2021Assignee: Tool, Inc.Inventors: William P. Liteplo, Jason G. Sidman, Eric A. Miller, Jr., Michael D. Tinstman, Arnold J. Herberg, Paul DiTullio, Marcus R. Hanna, Thomas Gernetzke, John D. Fiegener, Ryan Thompson, Daniel Bloch
-
Publication number: 20190069624Abstract: A device for dissipating forces on a helmet is described. The device includes first and second dissipation layers, each having a leaf spring. A helmet including such device is further described. A leaf spring for dissipating forces on a curved object is also described.Type: ApplicationFiled: October 30, 2018Publication date: March 7, 2019Inventors: Zoltan Mesko, Benjamin R. Rizzo, John D. Fiegener, Paul DiTullio, William P. Liteplo, Thomas Gernetzke, Marcus R. Hanna
-
Publication number: 20190031139Abstract: A seatbelt system comprising a buckle; a spool with a ratchet wheel and webbing that is windable onto or off of the spool as the spool rotates. A control mechanism is operatively engaged with a pawl located proximate the ratchet wheel. When the control mechanism is in a first condition, the pawl is disengaged from the ratchet wheel and the ratchet wheel and spool are rotatable to wind the webbing onto or off of the spool. When the control mechanism is in a second condition, the pawl is moved into engagement with the ratchet wheel and the ratchet wheel and spool are only able to rotate the webbing onto the spool. The control mechanism includes electronic switches and sensors that have to be actuated along with engaging the locking tongue in the buckle in order to move the pawl into engagement with the ratchet wheel.Type: ApplicationFiled: October 3, 2018Publication date: January 31, 2019Inventors: William P. Liteplo, Jason G. Sidman, Eric A. Miller, JR., Michael D. Tinstman, Arnold J. Herberg, Paul DiTullio, Marcus R. Hanna, Thomas Gernetzke, John D. Fiegener, Ryan Thompson, Daniel Bloch
-
Patent number: 7928064Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: November 14, 2005Date of Patent: April 19, 2011Assignee: GTC Biotherapeutics, Inc.Inventors: Paul DiTullio, Harry M. Meade, Edward S. Cole
-
Publication number: 20080176786Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: ApplicationFiled: November 14, 2005Publication date: July 24, 2008Inventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
-
Patent number: 7326679Abstract: The invention provides compositions and methods for inhibiting angiogenesis associated with tumors and reducing tumor growth.Type: GrantFiled: October 29, 2004Date of Patent: February 5, 2008Assignee: TranXenoGen, Inc.Inventors: Nathan H. Sloane, Kathleen M. Hehir, Alexander Baguisi, Paul DiTullio
-
Publication number: 20060179493Abstract: The invention provides a method of making and secreting a non-secreted protein. The method includes expressing the protein from a nucleic acid construct which includes: (a) a mammary epithelial specific promoter; (b) a milk protein specific signal sequence which can direct the secretion of a protein; (c) optionally, a sequence which encodes a sufficient portion of the amino terminal coding region of a secreted protein to allow secretion in the milk of a transgenic mammal, of the non-secreted protein; and (d) a sequence which encodes a non-secreted protein, wherein elements (a), (b), optionally (c), and (d) are preferably operatively linked in the order recited. Both glutamic acid decarboxylase (GAD) and myelin basic protein (MBP), which are cytoplasmic proteins, have been produced by the methods of the present invention. The invention also provides methods for treating diabetes and multiple sclerosis using proteins produced by the methods of the present invention.Type: ApplicationFiled: April 20, 2006Publication date: August 10, 2006Inventors: Harry Meade, Li-How Chen, Paul DiTullio
-
Patent number: 7019193Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: July 2, 2002Date of Patent: March 28, 2006Assignee: GTC Biotherapeutics, Inc.Inventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
-
Publication number: 20050239703Abstract: The invention provides compositions and methods for inhibiting angiogenesis associated with tumors and reducing tumor growth.Type: ApplicationFiled: October 29, 2004Publication date: October 27, 2005Inventors: Nathan Sloane, Kathleen Hehir, Alexander Baguisi, Paul DiTullio
-
Publication number: 20040163141Abstract: The invention features a method of delivering DNA to a spermatogonium by infusing DNA in situ into a testicle of a non-human animal and administering a condition or substance to the testicle to increase uptake of DNA by the spermatogoniumType: ApplicationFiled: February 3, 2004Publication date: August 19, 2004Inventors: Paul A. DiTullio, Karl M. Ebert
-
Publication number: 20040072302Abstract: The invention features a method of producing an antibody to a target antigen in an animal by contacting said animal with a genetically-matched cell containing a heterologous nucleic acid encoding the target antigen.Type: ApplicationFiled: July 15, 2003Publication date: April 15, 2004Inventors: Paul DiTullio, Kathleen M. Hehir
-
Patent number: 6686199Abstract: The invention features a method of delivering DNA to a spermatogonium by infusing DNA in situ into a testicle of a non-human animal and administering a condition or substance to the testicle to increase uptake of DNA by the spermatogonium.Type: GrantFiled: February 9, 1999Date of Patent: February 3, 2004Assignee: Tran Xenogen, Inc.Inventors: Paul A. DiTullio, Karl M. Ebert
-
Publication number: 20040006776Abstract: A method for the production of monoclonal antibodies in mammal's milk, through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.Type: ApplicationFiled: January 23, 1998Publication date: January 8, 2004Applicant: Genzyme Transgenics CorporationInventors: HARRY MEADE, PAUL DITULLIO, DANIEL POLLOCK
-
Publication number: 20030213003Abstract: The invention provides a method of making and secreting a non-secreted protein. The method includes expressing the protein from a nucleic acid construct which includes: (a) a mammary epithelial specific promoter; (b) a milk protein specific signal sequence which can direct the secretion of a protein; (c) optionally, a sequence which encodes a sufficient portion of the amino terminal coding region of a secreted protein to allow secretion in the milk of a transgenic mammal, of the non-secreted protein; and (d) a sequence which encodes a non-secreted protein, wherein elements (a), (b), optionally (c), and (d) are preferably operatively linked in the order recited. Both glutamic acid decarboxylase (GAD) and myelin basic protein (MBP), which are cytoplasmic proteins, have been produced by the methods of the present invention. The invention also provides methods for treating diabetes and multiple sclerosis using proteins produced by the methods of the present invention.Type: ApplicationFiled: February 4, 2003Publication date: November 13, 2003Inventors: Harry Meade, Li-How Chen, Paul DiTullio
-
Publication number: 20030096974Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: ApplicationFiled: July 2, 2002Publication date: May 22, 2003Applicant: Genzyme Transgenics Corporation, a Massachusetts corporationInventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
-
Patent number: 6528699Abstract: The invention provides a method of making and secreting a non-secreted protein. The method includes expressing the protein from a nucleic acid construct which includes: (a) a mammary epithelial specific promoter; (b) a milk protein specific signal sequence which can direct the secretion of a protein; (c) optionally, a sequence which encodes a sufficient portion of the amino terminal coding region of a secreted protein to allow secretion in the milk of a transgenic mammal, of the non-secreted protein; and (d) a sequence which encodes a non-secreted protein, wherein elements (a), (b), optionally (c), and (d) are preferably operatively linked in the order recited. Both glutamic acid decarboxylase (GAD) and myelin basic protein (MBP), which are cytoplasmic proteins, have been produced by the methods of the present invention. The invention also provides methods for treating diabetes and multiple sclerosis using proteins produced by the methods of the present invention.Type: GrantFiled: February 24, 1998Date of Patent: March 4, 2003Assignee: Genzyme Transgenics CorporationInventors: Harry Meade, Li-How Chen, Paul DiTullio
-
Publication number: 20030037348Abstract: The invention features a method of delivering DNA to a spermatogonium by infusing DNA in situ into a testicle of a non-human animal and administering a condition or substance to the testicle to increase uptake of DNA by the spermatogonium.Type: ApplicationFiled: February 9, 1999Publication date: February 20, 2003Inventor: PAUL A. DITULLIO
-
Patent number: 6441145Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: August 28, 1998Date of Patent: August 27, 2002Assignee: Genzyme Transgenics, Inc.Inventors: Paul DiTullio, Harry Meade, Edward S. Cole
-
Patent number: 5849992Abstract: A method for the production of monoclonal antibodies in mammal's milk through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.Type: GrantFiled: March 27, 1995Date of Patent: December 15, 1998Assignee: Genzyme Transgenics CorporationInventors: Harry Meade, Paul Ditullio, Daniel Pollock
-
Patent number: 5843705Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: February 21, 1995Date of Patent: December 1, 1998Assignee: Genzyme Transgenic CorporationInventors: Paul DiTullio, Harry Meade, Edward S. Cole